Human iPSC-Derived Cardiac Organoid differentiation Kit
1273.56 EUR
In Stock
quantity
Produktdetaljer
Katalognummer: 716 - RIPO-HWM002K-1
Produktkategori: Företag och industri > Vetenskap och laboratorium
Gentaur
Storlek: 1kit
Parameters
| Additional information | N/A |
|---|---|
| Storage and shipping | -20℃ Blue ice |
RIPO-HWM002K-1kit
Human iPSC-Derived Cardiac Organoid differentiation Kit
Human iPSC-Derived Cardiac Organoid Differentiation Kit is expressed from Human
1273.56 €
ABC-SC0074T
HighQC™ Human IPSC-Derived Neural Stem Cell MAPT P301L HET
Human Human IPSC-Derived Neural Stem Cells that have been genetically edited using CRISPR-Cas9 technology to introduce the P301L mutation (CGGandamp;gt;TGG) into the MAPT gene. This line is homozygous for the P301L mutation so both alleles contain the mutation.
Ask for quotation
ABC-SC0067T
HighQC™ Human IPSC-Derived Neural Stem Cell LRRK2 G2019S HOM
Human Human IPSC-Derived Neural Stem Cells that have been genetically edited using CRISPR-Cas9 technology to introduce the G2019S mutation (GGCandgt;AGC) in the LRRK2 gene. This line is homozygous for the G2019S mutation so both alleles contain the mutation.The G2019S mutation in LRRK2 has been implicated in autosomal-dominant familial Parkinson's disease with late onset (Fonzo et al., 2006, Thaler et al., 2009). The G2019S mutation increases the kinase activity of LRRK2 causing increased autophosphorylation and substrate phosphorylation that may affect neuronal cell health in Parkinson's disease patients (West et al., 2005).
Ask for quotation
ABC-SC0068T
HighQC™ Human IPSC-Derived Neural Stem Cell LRRK2 G2019S HET
Human Human IPSC-Derived Neural Stem Cells that have been genetically edited using CRISPR-Cas9 technology to introduce the G2019S mutation (GGCandgt;AGC) in the LRRK2 gene. This line is heterozygous for the G2019S mutation where one allele contains the mutation and the other allele is wild type at the locus.The G2019S mutation in LRRK2 has been implicated in autosomal-dominant familial Parkinson's disease with late onset (Fonzo et al., 2006, Thaler et al., 2009). The G2019S mutation increases the kinase activity of LRRK2 causing increased autophosphorylation and substrate phosphorylation that may affect neuronal cell health in Parkinson's disease patients (West et al., 2005).
Ask for quotation
Håll dig uppdaterad! Visa tidigare publikationer
By: Author , 2 Comment
Anaplasmos hos hundar och katter – allt du behöver veta
23 August 2025
By: Author , 2 Comment
Solbränna – hur leker man säkert i solen?
16 August 2025
By: Author , 2 Comment
Biologiska läkemedel – Modernitet inom farmaci
1 August 2025
By: Author , 2 Comment
Icke-steroida antiinflammatoriska läkemedel – viktig information om populära läkemedel
22 July 2025